Respiratory Infectious Disease
Quality Regulatory Clinical Ireland Limited focuses on pulmonary tuberculosis, with particular interest in rifampicin-resistant tuberculosis and multidrug-resistant tuberculosis affecting the lungs.
- Mycobacterium tuberculosis infection control
- Drug-resistant tuberculosis
- Pulmonary infection
The sponsor’s research activity is centered on clinical management of resistant tuberculosis within a respiratory medicine context.
Host-Directed Therapy
The funded research examines adjunctive host-directed therapies for tuberculosis, including both anti-inflammatory and antimicrobial approaches.
- Adjunctive anti-inflammatory therapy
- Adjunctive antimicrobial therapy
- Immune modulation
This area reflects an interest in therapies that support treatment of resistant pulmonary infection beyond standard antimycobacterial care.
Pulmonary Function Recovery
Clinical interest extends to recovery of lung function in patients with active pulmonary disease, with attention to measures of respiratory improvement during treatment.
- Forced expiratory volume
- Respiratory recovery
- Stable sputum conversion
These outcomes place emphasis on restoration of pulmonary health alongside infection clearance.
Anti-Infective Efficacy
The sponsor also funds research relevant to microbial eradication and treatment response in resistant tuberculosis, with a focus on clearing Mycobacterium tuberculosis infection.
- Infection eradication
- Treatment response
- Resistant pulmonary disease
This area links infectious disease control with clinical outcomes in difficult-to-treat pulmonary infection.
